MyoKardia, Inc. (NASDAQ:MYOK) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, August 5th.
A number of other research analysts have also commented on MYOK. TheStreet lowered MyoKardia from a “c-” rating to a “d+” rating in a research report on Friday, May 19th. BMO Capital Markets reaffirmed an “outperform” rating and set a $32.00 price target on shares of MyoKardia in a research report on Wednesday, May 10th. Finally, Zacks Investment Research lowered MyoKardia from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. MyoKardia presently has an average rating of “Buy” and an average target price of $37.60.
Shares of MyoKardia (NASDAQ:MYOK) traded up 7.37% on Friday, hitting $40.80. The company’s stock had a trading volume of 825,825 shares. The stock’s 50-day moving average price is $18.02 and its 200-day moving average price is $14.27. MyoKardia has a 52 week low of $10.55 and a 52 week high of $41.05. The firm’s market cap is $1.28 billion.
MyoKardia (NASDAQ:MYOK) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.04. The business had revenue of $5.60 million for the quarter, compared to the consensus estimate of $6.73 million. MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The company’s revenue for the quarter was up 60.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.37) EPS. Equities analysts expect that MyoKardia will post ($1.64) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://stocknewstimes.com/2017/08/15/myokardia-inc-nasdaqmyok-raised-to-strong-buy-at-bidaskclub-updated.html.
In related news, insider Anastasios Gianakakos sold 32,988 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $15.00, for a total value of $494,820.00. Following the sale, the insider now owns 541,151 shares in the company, valued at approximately $8,117,265. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph Lambing sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $30.00, for a total value of $450,000.00. Following the completion of the sale, the insider now owns 119,718 shares in the company, valued at approximately $3,591,540. The disclosure for this sale can be found here. Insiders have sold a total of 67,288 shares of company stock worth $1,441,236 in the last quarter. Company insiders own 46.10% of the company’s stock.
Several hedge funds have recently bought and sold shares of MYOK. Fernwood Investment Management LLC increased its stake in MyoKardia by 0.8% in the first quarter. Fernwood Investment Management LLC now owns 43,323 shares of the biotechnology company’s stock valued at $570,000 after buying an additional 327 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of MyoKardia by 2.5% in the second quarter. Wells Fargo & Company MN now owns 18,539 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 455 shares in the last quarter. Fiduciary Trust Co. increased its stake in shares of MyoKardia by 7.2% in the second quarter. Fiduciary Trust Co. now owns 30,612 shares of the biotechnology company’s stock valued at $401,000 after buying an additional 2,058 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of MyoKardia by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 43,680 shares of the biotechnology company’s stock valued at $575,000 after buying an additional 2,394 shares in the last quarter. Finally, Nationwide Fund Advisors increased its stake in shares of MyoKardia by 36.3% in the second quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 2,591 shares in the last quarter. Institutional investors own 47.63% of the company’s stock.
MyoKardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
